Get started
Author

Dustin McCurry

Observed names: D. McCurry, Dustin B McCurry, Dustin B. McCurry, Dustin Barrett McCurry
Observed institutions: University of Southern California, Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of Pittsburgh, UPMC Health System, Mayo Clinic in Arizona, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
ORCID: 0000-0003-0585-3259
Observed ORCID: 0000-0003-0585-3259
OpenAlex ID: A5013312057
A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor Microenvironment
2010 · Angela D. Pardee, Dustin McCurry, et al. · Cancer Research · 56
PDF
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
2016 · Vani Lakshminarayanan, Nitin T. Supekar, et al. · PLoS ONE · 54
PDF
Myeloid-derived Suppressor Cells Adhere to Physiologic STAT3- vs STAT5-dependent Hematopoietic Programming, Establishing Diverse Tumor-Mediated Mechanisms of Immunologic Escape
2012 · Peter A. Cohen, Jennifer S. Ko, et al. · Immunological Investigations · 42
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
2025 · Tejas Jammihal, Renee Maria Saliby, et al. · Nature Cancer · 38
PDF
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2021 · Yana G. Najjar, Dustin McCurry, et al. · Clinical Cancer Research · 26
Surrogatein vitroactivation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens
2016 · Latha B. Pathangey, Dustin B. McCurry, et al. · Oncotarget · 26
PDF
Severe anaplasmosis represents a treatable cause of secondary hemophagocytic lymphohistiocytosis: Two cases and review of literature
2020 · Joseph M. Rocco, Christina Mallarino-Haeger, et al. · Ticks and Tick-borne Diseases · 16
Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study
2018 · Esad Boskailo, Aldin Malkoc, et al. · Acta Medica Academica · 13
PDF
A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.
2019 · Yana Najjar, Dustin McCurry, et al. · Journal of Clinical Oncology · 6
CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy
2023 · Ajlan Al Zaki, Dustin McCurry, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 5
Immune-based therapies in diffuse large B-cell lymphoma
2023 · Dustin McCurry, Christopher R. Flowers, et al. · Expert Opinion on Investigational Drugs · 3
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes
2025 · Yu-Hsiang Chen, Timothy Bi, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
2025 · Renee Maria Saliby, Chris Labaki, et al. · Journal of Clinical Oncology · 1
1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
2023 · R.M. Saliby, T. Jammihal, et al. · Annals of Oncology · 1
PDF
Abstract IA025: Senescence-driven CD4 exhaustion establishes a therapeutically targetable immune-evasive niche in African ancestry-associated diffuse large B-cell lymphoma
2026 · Sanket Shah, Michelle J. Lee, et al. · Cancer Epidemiology Biomarkers & Prevention
Temporal trends in relative survival and excess mortality among US adults with lymphoid malignancies
2026 · Bryan Valcarcel, Veronica Leautaud, et al. · JNCI Journal of the National Cancer Institute
EXABS-150-MDS: Mechanisms of Measurable Residual Disease Progression for Myelodysplastic Syndromes After Allogeneic Stem Cell Transplantation
2026 · Yu-Hsiang Chen, Timothy Bi, et al. · Clinical Lymphoma Myeloma & Leukemia
1228 Immune escape through oncogene-mediated editing of the HLA-ligandome
2025 · Dustin B McCurry, Emerie E Danson, et al. · Regular and Young Investigator Award Abstracts
PDF
ASXL1 truncating mutations drive leukemic resistance to T cell attack
2025 · Dustin McCurry, Zhongqi Ge, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
ASXL1 Truncating Mutations Drive Leukemic Resistance to T Cell Attack
2023 · Dustin McCurry, Zhongqi Ge, et al. · Blood
PDF
Phase 1 Dose Escalation Study of Pembrolizumab in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Large B-Cell or Follicular Lymphoma Following Progression after Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy
2023 · Dustin McCurry, Jason Westin, et al. · Blood
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023 · Yana G. Najjar, Dustin McCurry, et al.
Supplementary figure legend 1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023 · Yana G. Najjar, Dustin McCurry, et al.
Supplementary Figure S2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023 · Yana G. Najjar, Dustin McCurry, et al.
Supplementary Figure S1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
2023 · Yana G. Najjar, Dustin McCurry, et al.
Works count: 45
Citation count: 288
H-index: 8
I10-index: 8
Year
Topic
Type